The specter of Pharma generic competition has consistently loomed over copyright’s iconic drug, Sildenafil, sparking questions about the future of similar drug stakes. While initial periods saw impressive returns, the exclusivity lapse has opened the way for cheaper substitutes, possibly lowering revenue and posing a genuine danger for shareholde